Breaking News

Dying of a disease "I never knew existed"; a mother whose son died of a rare disease urges the FDA to rethink trials for them

    

 

First Opinion

An author describes dying of a disease "I never knew about." A health care pricing expert looks at the rise in launch prices for new drugs. The mother of a son who died of a rare disease challenges the FDA to think differently about trials for them. You can read these and the rest of this week's First Opinion essays here. Podcast fans: The First Opinion Podcast is back. This week's episode is a conversation with a pediatric cancer research who has ALS, exploring the slow pace of drug approvals for this and other neurologic conditions.

Dying of a disease I never knew existed

By Richard B. Woodward

Adobe

Idiopathic pulmonary fibrosis kills about 40,000 Americans each year, yet few have heard of this "irremediable" lung disease.

Read More

The FDA needs to be more flexible in assessing treatments for rare diseases, like the one that seemed to help my son

By Karen Quandt

Maria Fabrizio for STAT

Clinical trials for rare diseases can be incredibly valuable. But they can also have devastating limitations.

Read More

Launch prices: tackling the next drug pricing challenge

By Steve Pearson

Adobe

The Inflation Reduction Act could prompt pharmaceutical companies to push U.S. drug launch prices to even higher levels.

Read More

Listen: A doctor with ALS laments the slow pace for drug approval

By Patrick Skerrett

William Woods talks about living with ALS and watching what he sees as the glacial pace of approving an experimental drug called AMX0035.

Read More

The FDA got it right with hearing aids. Updating Medicare coverage is next

By Nicholas S. Reed and Frank R. Lin

Joe Raedle/Getty

FDA regulations on OTC hearing aids are a big step forward. Now Medicare needs to cover them, and hearing services provided by audiologists.

Read More

Breaking the 'corporate medical playbook' that silences physicians' reports of inequity

By Pringl Miller

Adobe

A new organization aims to study the who, what, where, why, and how of workplace injustices and to support those who have been targeted.

Read More

Health care's shift from covenant to commodity comes with consequences

By Peter A. Bonis

Gandalf's Gallery/Flickr

The shift in health care from a covenant between physician and patient to a commodity chips away at the human connection.

Read More

Open access to research can close gaps for people with disabilities

By Bonnielin Swenor and JR Rizzo

Adobe

As open access policies regarding research access take shape, the unique barriers faced by people with disabilities must be considered.

Read More

Congress should not compel Medicare to pay for liquid biopsies

By H. Gilbert Welch

Gillian Flaccus/AP

Until a trial shows that a liquid biopsy to detect early cancer helps more than it harms, Medicare should not be compelled to pay for it.

Read More

Sunday, September 11, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments